[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pneumococcal-infectious-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pneumococcal-infectious-disease":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,42,64],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100577589","phase-1-clinical-trial-of-pcv24-in-infants-aged-2-23-months-100577589",false,"NCT06800261","Clinical Trial of PCV24 in Infants Aged 2-23 Months","A Randomized, Double-blind, Positive Controlled Phase Ib Clinical Trial to Evaluate the Safety and Immunogenicity of 24-valent Pneumococcal Conjugate Vaccine in Children Aged 2 (Minimum 42 Days)-23 Months","Inclusion Criteria:\n\n1. Healthy infants who are aged 2 months (42-89 days), 7-11 months, 12-23 months;\n2. Participants' guardian provides legal identity document and participants' vaccination record;\n3. Participants' guardian understands and voluntarily signs the informed consent form;\n4. Follow all study procedures and stay in contact during the study.\n\nExclusion Criteria:\n\n1. Received any pneumococcal vaccine prior to enrollment;\n2. History of invasive pneumococcal diseases or other pneumococcal diseases caused by Streptococcus pneumoniae, as confirmed by laboratory tests;\n3. History of severe adverse reactions to the vaccine or vaccine components, or history of allergy, such as urticaria, dyspnea, angioneurotic edema, anaphylactic shock;\n4. Low birth weight (\\\u003C2.5kg), or premature infant (gestation weeks \\\u003C 37 weeks) (applies to infants younger than 12 months);\n5. History of abnormal labor during delivery (planned cesarean section is excluded), history of asphyxia rescue and nervous system damage (applies to infants younger than 12 months);\n6. Congenital malformations or developmental disorders, genetic defects, severe malnutrition;\n7. Have uncontrolled chronic diseases or history of severe diseases, including but not limited to cardiovascular diseases (e.g. congenital heart disease), hematological diseases (e.g. severe anemia), liver and kidney diseases, digestive diseases, respiratory diseases (such as active tuberculosis), malignant tumors and major functional organ transplantation history;\n8. Autoimmune diseases, immunodeficiency diseases (including but not limited to systemic lupus erythematosus, rheumatoid arthritis, autoimmune thyroid disease, asplenia, functional asplenia, HIV infection);\n9. Diagnosed abnormal blood coagulation function (eg, lack of blood coagulation factors, blood coagulopathy, abnormal platelets level), potential bleeding (history of obvious bleeding, hematoma or bruising after intramuscular injection or venipuncture).\n10. Have\u002Fhave suffered from a serious neurological disorder (epilepsy or convulsions, but febrile convulsion is not an exclusion criteria ) or mental illness or have a family history of such diseases.\n11. Consecutively received immunosuppressive therapy (excluding corticosteroid spray therapy for allergic rhinitis and surface corticosteroid therapy for acute non-concurrent dermatitis), or other immunoregulatory therapies, or cytotoxic therapy over 14 days within 6 months before vaccination, or plans to receive such therapies during the study.\n12. Received blood products prior to enrollment within 3 months prior to enrollment, or plans to receive such therapies during the study. Receipt of Hepatitis B immunoglobulin one month prior to enrollment is an exception.\n13. Received other investigational drugs or vaccines within 30 days prior to enrollment, or plan to receive such drugs or vaccines during the study;\n14. Received live attenuated vaccine within 14 days prior to enrollment;\n15. Received subunit or inactivated vaccine within 7 days prior to enrollment;\n16. Acute diseases or acute onset of chronic diseases within 7 days prior to enrollment, known or potentially active infection;\n17. Axillary temperature≥ 37.3 Degree Celsius before vaccination;\n18. In the investigator's judgment, the participant has any other factors that make him or her unfit to participate in the clinical trial.",true,"ALL","42 Days","23 Months",{"count":21,"type":22},180,"ESTIMATED","INTERVENTIONAL",[25],"PHASE1","A Phase 1b clinical trial of 24-valent pneumococcal conjugate vaccine (PCV24) developed by Sinovac Life Science Co., Ltd will be conducted in pediatric population aged 2 months (minimum 42 days)-23 months.\n\nThe objective of the study is to evaluate the safety and immunogenicity of Sinovac PCV24. The trial is a randomized, double-blind, positive controlled phase Ib clinical trial.",[28],"Pneumococcal Infectious Disease","RECRUITING","2026-01-26",{"date":32,"type":33},"2026-01-28","ACTUAL",{"date":35,"type":33},"2025-05-08",{"date":37,"type":22},"2026-06",{"name":39,"class":40},"Sinovac Life Sciences Co., Ltd.","INDUSTRY",2,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":16,"sex":17,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":23,"phases":53,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":57,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":63},"100563557","phase-3-clinical-trial-of-13-valent-pneumococcal-conjugate-vaccine-100563557","NCT06617715","Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine","A Phase Ⅲ Clinical Study to Evaluate the Safety and Immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (PCV13) in Healthy Infants","Inclusion Criteria:\n\n1. Healthy infants or children who are aged 2 months (at least 6 weeks), 7-11 months, 12-23 months and 2-5 years (before the 6th birthday);\n2. Participants' guardians provide legal identity document and participants' vaccination record;\n3. Participants' guardians understand and voluntarily sign the informed consent form;\n4. Participants' guardians can follow all study procedures and stay in contact during the study.\n\nExclusion Criteria:\n\n1. Received any pneumococcal vaccine prior to enrollment;\n2. History of bacterial pneumonia or invasive pneumococcal diseases (IPDs) caused by Streptococcus pneumoniae, as confirmed by laboratory tests;\n3. History of allergy or adverse reactions to the vaccine or vaccine components, or history of allergy, such as urticaria, dyspnea, angioedema and abdominal pain;\n4. History of dystocia, asphyxia rescue and nervous system damage at birth for infants under 2 years of age;\n5. Congenital malformations or developmental disorders, genetic defects, severe malnutrition, history of asthma;\n6. Autoimmune diseases (such as systemic lupus erythematosus), immunodeficiency diseases or immunosuppressive diseases (such as AIDS, organ transplantation);\n7. Severe cardiovascular diseases, diabetes, liver diseases, kidney diseases, malignant tumours.\n8. Have\u002Fhave suffered from a serious neurological disorder (epilepsy or convulsions) or mental illness or have a family history of such diseases.\n9. History of thyroidectomy, asplenia, functional asplenia; asplenia or splenectomy caused by any reasons;\n10. Diagnosed abnormal blood coagulation function (eg, lack of blood coagulation factors, blood coagulopathy, abnormal platelets level), history of obvious bleeding, hematoma or bruising after intramuscular injection or venipuncture.\n11. Consecutively received ≥14 days of corticosteroid, any other immunosuppressive therapy (excluding corticosteroid spray therapy for allergic rhinitis and surface corticosteroid therapy for acute non-concurrent dermatitis), or cytotoxic therapy prior to enrollment for infants aged 6 weeks to 2 months or within 6 months prior to enrollment for children aged 7 months to 5 years.\n12. Received blood products prior to enrollment for children aged 2 months or within 3 months prior to enrollment for children aged 7 months to 5 years. Receipt of Hepatitis B immunoglobulin one month prior to enrollment is an exception.\n13. Received other investigational drugs within 60 days prior to enrollment, or plan to receive such drugs during the study;\n14. Received live attenuated vaccine within 14 days prior to enrollment;\n15. Received subunit or inactivated or other vaccine within 7 days prior to enrollment;\n16. Acute diseases or acute onset of chronic diseases within 7 days prior to enrollment;\n17. Had fever (axillary temperature≥ 37.3 Degree Celsius) before vaccination;\n18. In the investigator's judgment, the participant has any other factors that make him or her unfit to participate in the clinical trial.","6 Weeks","5 Years",{"count":52,"type":22},3080,[54],"PHASE3","A Phase Ⅲ clinical trial of 13-valent pneumococcal conjugate vaccine (PCV13) developed by Sinovac Life Science Co., Ltd will be conducted in pediatric population aged 2 months (minimum 6 weeks)-5 years (before 6th birthday). The objective of the study is to evaluate the immunogenicity and safety of Sinovac PCV13.",[28],{"date":32,"type":33},{"date":59,"type":33},"2024-10-23",{"date":61,"type":22},"2026-07-30",{"name":39,"class":40},1,{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":50,"enrollmentInfo":71,"targetDuration":4,"studyType":23,"phases":73,"briefSummary":75,"conditions":76,"keywords":77,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":5},"100616056","phase-2-clinical-trial-of-pcv24-in-infants-and-children-aged-2-months-to-5-years-100616056","NCT07300644","Clinical Trial of PCV24 in Infants and Children Aged 2 Months to 5 Years","A Randomized, Double-blind, Positive-controlled Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of 24-valent Pneumococcal Conjugate Vaccine in Children Aged 2 Months (Minimum 42 Days) to 5 Years","Inclusion Criteria:\n\n1. Healthy infants who are aged 2 months (42-89 days), 7-11 months, 12-23 months, and 2-5 years;\n2. The participants' guardian provides a legal identity document and the participants' vaccination record;\n3. The participant's guardian understands and voluntarily signs the informed consent form;\n4. Follow all study procedures and stay in contact during the study.\n\nExclusion Criteria:\n\n1. Received any pneumococcal vaccine prior to enrollment;\n2. History of invasive pneumococcal diseases or other pneumococcal diseases caused by Streptococcus pneumoniae, as confirmed by laboratory tests;\n3. History of severe adverse reactions to the vaccine or vaccine components, or history of allergy, such as urticaria, dyspnea, angioneurotic edema, anaphylactic shock;\n4. Low birth weight (\\\u003C2.5kg), or premature infant (gestation weeks \\\u003C 37 weeks) (applies to infants younger than 12 months);\n5. History of abnormal labor during delivery (planned cesarean section is excluded), history of asphyxia rescue and nervous system damage (applies to infants younger than 12 months);\n6. Severe congenital malformations or developmental disorders, genetic defects, or malnutrition;\n7. Have uncontrolled chronic diseases or history of severe diseases, including but not limited to cardiovascular diseases (e.g. congenital heart disease), hematological diseases (e.g. severe anemia), liver and kidney diseases, digestive diseases, respiratory diseases (such as active tuberculosis), malignant tumors and major functional organ transplantation history;\n8. Autoimmune diseases, immunodeficiency diseases (including but not limited to systemic lupus erythematosus, rheumatoid arthritis, autoimmune thyroid disease, asplenia, functional asplenia, HIV infection);\n9. Diagnosed abnormal blood coagulation function (eg, lack of blood coagulation factors, blood coagulopathy, abnormal platelet levels);\n10. Have\u002Fhave suffered from a serious neurological disorder (epilepsy or convulsions, but a febrile convulsion is not an exclusion criteria ) or mental illness, or have a family history of such diseases;\n11. Consecutively received immunosuppressive therapy (excluding corticosteroid spray therapy for allergic rhinitis and surface corticosteroid therapy for acute non-concurrent dermatitis), or other immunoregulatory therapies, or cytotoxic therapy over 14 days within 6 months before vaccination, or plans to receive such therapies during the study;\n12. Receipt of immunoglobulins or other blood products within 3 months prior to administration of the investigational vaccine (except for hepatitis B immunoglobulin or rabies immunoglobulin used within 1 month), or planned use of such products during the study period;\n13. Received other investigational drugs or vaccines within 30 days prior to enrollment, or plan to receive such drugs or vaccines during the study;\n14. Received live attenuated vaccine within 14 days prior to enrollment;\n15. Received subunit or inactivated vaccine within 7 days prior to enrollment;\n16. Acute diseases or acute onset of chronic diseases within 7 days prior to enrollment, known or potentially active infection;\n17. Axillary temperature≥ 37.3 Degree Celsius before vaccination;\n18. In the investigator's judgment, the participant has any other factors that make him or her unfit to participate in the clinical trial.",{"count":72,"type":22},420,[74],"PHASE2","A Phase 2 clinical trial of 24-valent pneumococcal conjugate vaccine (PCV24) developed by Sinovac Life Science Co., Ltd will be conducted in the pediatric population aged 2 months (minimum 42 days) to 5 years.\n\nThe objective of the study is to evaluate the safety and immunogenicity of Sinovac PCV24. The trial is a randomized, double-blind, positive controlled phase 2 clinical trial.",[28],[78,79],"PCV24","Phase 2","2025-12-17",{"date":82,"type":33},"2025-12-24",{"date":84,"type":33},"2025-11-25",{"date":86,"type":22},"2027-12",{"name":39,"class":40}]